Clinical trials: Epithelial Neoplasms, Malignant
Liver Cancer, Hepatocellular Carcinoma
Application of mRNA Immunotherapy Technology in Hepatitis B Virus-related Refractory Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of mRNA vaccine for HBV-positive Advanced Hepatocellular Carcinoma.
- Trial name
- NCT05738447
- Testing
- HBV mRNA vaccine
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- West China Hospital
Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma
Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer
This phase II trial studies the effect of re-irradiation with NBTXR3 in combination with pembrolizumab in treating patients with head and neck squamous cell cancer that cannot be removed by surgery (inoperable) and has come back…
- Trial name
- NCT04834349
- Testing
- Hafnium Oxide-containing Nanoparticles NBTXR3, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy
- Sponsor
- M.D. Anderson Cancer Center
Renal Cancer, Renal Clear Cell Carcinoma
CD70-targeted immunoPET Imaging of Malignant Cancers
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma…
- Conditions
- Renal Cancer, Renal Clear Cell Carcinoma, Lymphoma, Lymphoma, Large B-Cell, Diffuse
- Trial name
- NCT06852638
- Testing
- [18F]F-RESCA-RCCB6, [18F]F-RESCA-R8B4, [68Ga]Ga-NOTA-R8B4
- Where
- China
- Volunteers
- 300 people
- Sponsor
- RenJi Hospital
Non-small Cell Lung Cancer
CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).
This study was a one-arm, single-center, phase II clinical study. Patients who meet the enrollment criteria will receive CM082 tablets 150mg once daily (qd) orally (taken within half an hour after daily breakfast) in combination…
- Trial name
- NCT03848611
- Testing
- CM082 plus JS001
- Where
- China
- Volunteers
- 20 people
- Sponsor
- AnewPharma
Basal Cell Carcinoma
Remote Assessment of OCT Scans for BCC Detection
Basal cell carcinoma (BCC) is the most common form of cancer and entails approximately 80% of all cutaneous malignancies. This locally destructive neoplasm is commonly diagnosed by punch biopsy which is considered painful, causes…
- Trial name
- NCT06273709
- Testing
- Vivosight Multi-beam Swept-Source Frequency Domain OCT scanner
- Volunteers
- 120 people
- Sponsor
- Maastricht University Medical Center
Locally Advanced, Urothelial Carcinoma Ureter
Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer
In this study, we propose to conduct an ambispective study to analyze the safety of preserved renal unit surgery combined with postoperative adjuvant radiotherapy in patients with limited stage ureteral cancer with high risk…
- Trial name
- NCT06120387
- Testing
- Radical surgery, Kidney sparing surgery+Postoperative radiotheray
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Xuesong Li
Head and Neck Neoplasms
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage…
- Trial name
- BelieveIT-201 (NCT05980598)
- Testing
- TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 β/γ
- Where
- 65 sites in United States, Georgia and 6 more
- Volunteers
- 27 people
- Sponsor
- Ascendis Pharma A/S
Metastatic Microsatellite Stable Colorectal Carcinoma
Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Phase 1b/2 open-label study evaluates the safety, tolerability, and efficacy of combination immunotherapy with nadunolimab (anti-IL-1RAP) and toripalimab (anti-PD-1) in patients with chemotherapy-refractory metastatic…
- Trial name
- NCT07281716
- Testing
- Nadunolimab, Toripalimab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Dan Feng
Carcinoma, Renal Cell
Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
To investigate safety and efficacy of single agent sunitinib malate as first-line systemic therapy in Chinese patients with metastatic renal cell carcinoma.
- Trial name
- MRCC RCC (NCT00706706)
- Testing
- Sunitinib Malate (SU011248)
- Where
- 11 sites in China
- Volunteers
- 105 people
- Sponsor
- Pfizer
Renal Cell Carcinoma (RCC)
First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain
This retrospective observational study will use anonymized electronic medical records from the BIG-PAC® database to describe outcomes and treatment management for adults in Spain with advanced or metastatic renal cell carcinoma…
- Trial name
- INSPIRE-RCC (NCT07852884)
- Testing
- First-line systemic regimens
- Where
- Spain
- Volunteers
- 1,200 people
- Sponsor
- Bristol-Myers Squibb
Fallopian Tube Cancer, Ovarian Cancer
TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of TLK286 in treating patients who have advanced ovarian…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00022347
- Testing
- canfosfamide hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Glioblastoma
Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma
The purpose of this study is to examine the use of activated T cells (ATCs) to assess the safety and tolerability of autologous activated T cells, as measured by the number of Grade 3 or higher toxicities, the number of serious…
- Trial name
- NCT05341947
- Testing
- Activated T cells
- Where
- United States
- Sponsor
- Jeremy Rudnick, M.D
Nevus, Dysplasia; Epithelial
Skin Fluorescent Imaging (SFI) System in Patients With Nevi
The Sponsor has developed the Skin Fluorescent Imaging (SFI) system, an in vivo imaging modality, for the purpose of providing physicians with insight into the biological changes occurring during tissue remodeling in a nevus.
- Trial name
- NCT04368247
- Testing
- Skin Fluorescent Imaging
- Where
- 4 sites in United States
- Volunteers
- 300 people
- Sponsor
- Orlucent, Inc
Kidney Cancer, Metastatic Cancer
Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain
This phase II trial is studying how well sorafenib works in treating patients with kidney cancer that has spread to the brain. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth…
- Trial name
- NCT00301847
- Testing
- sorafenib tosylate
- Where
- 12 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme
An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse
This single-arm, open-label, multicenter, observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in patients with glioblastoma multiforme in first or second relapse.
- Trial name
- NCT01618747
- Where
- 3 sites in Taiwan
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer, Non-Small Cell Lung Cancer
A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia
The purpose of this study is to investigate the safety of patients in Asia with Non-Small Cell Lung Cancer (NSCLC)who are treated with Nivolumab monotherapy as a second line or third line treatment.
- Trial name
- CheckMate870 (NCT03195491)
- Testing
- Nivolumab
- Where
- 30 sites in China, Thailand
- Volunteers
- 400 people
- Sponsor
- Bristol-Myers Squibb
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Early Stage Breast Carcinoma
Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy
Radiation therapy after surgery to remove breast cancer improves control of the breast cancer. Standard therapy after breast conservation surgery is five to six weeks of radiation to the entire breast.
- Trial name
- SIGNAL 2 (NCT02212860)
- Testing
- Stereotactic Body Radiation Then Surgery
- Where
- Canada
- Volunteers
- 139 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
EUS Guided Cyanoacrylate Injection, Endoscopic Variceal Band Ligation
EUS Glue vs Endoscopic Variceal Band Ligation for Prevention of Rebleeding in Patients With HCC and EV Bleeding: a Retrospective Comparative Study
SP by EUS-CYA improves clinical outcomes (eg, EV rebleeding) in patients with HCC and prior EV bleeding when compared with SP by EGD-VBL
- Conditions
- EUS Guided Cyanoacrylate Injection, Endoscopic Variceal Band Ligation, Hepatocelular Carcinoma, Esophageal Variceal Bleeding
- Trial name
- EUSgluevsVBL (NCT04918459)
- Where
- Hong Kong
- Volunteers
- 70 people
- Sponsor
- Chinese University of Hong Kong
Breast Carcinoma, Cardiomyopathy
TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer
This study examines TRPC6 in predicting and preventing chemotherapy related cardiac toxicity and heart failure in patients with breast cancer.
- Conditions
- Breast Carcinoma, Cardiomyopathy, Congestive Heart Failure
- Trial name
- NCT05507879
- Testing
- Biospecimen Collection, Electronic Medical Record
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.